277 related articles for article (PubMed ID: 36346100)
41. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
[No Abstract] [Full Text] [Related]
42. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
43. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.
Caliman E; Fancelli S; Petroni G; Gatta Michelet MR; Cosso F; Ottanelli C; Mazzoni F; Voltolini L; Pillozzi S; Antonuzzo L
Lung Cancer; 2023 Jan; 175():88-100. PubMed ID: 36493578
[TBL] [Abstract][Full Text] [Related]
44. Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.
McNamee N; da Silva IP; Nagrial A; Gao B
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175833
[TBL] [Abstract][Full Text] [Related]
45. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
Korde R; Veluswamy R; Allaire JC; Barnes G
Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
[TBL] [Abstract][Full Text] [Related]
46. Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions.
Allen J; Jahanzeb M
Clin Lung Cancer; 2008 Sep; 9(5):262-70. PubMed ID: 18953759
[TBL] [Abstract][Full Text] [Related]
47. Emerging therapies for small cell lung cancer.
Yang S; Zhang Z; Wang Q
J Hematol Oncol; 2019 May; 12(1):47. PubMed ID: 31046803
[TBL] [Abstract][Full Text] [Related]
48. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ; Paz-Ares L
JAMA Oncol; 2023 Mar; 9(3):419-429. PubMed ID: 36520421
[TBL] [Abstract][Full Text] [Related]
49. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
50. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
51. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
52. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
53. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
Tian Y; Ma J; Jing X; Zhai X; Li Y; Guo Z; Yu J; Zhu H
Cancer Lett; 2022 Aug; 541():215719. PubMed ID: 35597478
[TBL] [Abstract][Full Text] [Related]
54. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Ortega-Franco A; Ackermann C; Paz-Ares L; Califano R
ESMO Open; 2021 Feb; 6(1):100003. PubMed ID: 33450659
[TBL] [Abstract][Full Text] [Related]
55. New targeted therapies and small-cell lung cancer.
Rossi A; Maione P; Palazzolo G; Sacco PC; Ferrara ML; Falanga M; Gridelli C
Clin Lung Cancer; 2008 Sep; 9(5):271-9. PubMed ID: 18824449
[TBL] [Abstract][Full Text] [Related]
56. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract][Full Text] [Related]
57. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
58. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
59. First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Li L; Yang D; Min Y; Liao A; Zhao J; Jiang L; Dong X; Deng W; Yu H; Yu R; Zhao J; Shi A
BMC Cancer; 2023 Apr; 23(1):318. PubMed ID: 37024843
[TBL] [Abstract][Full Text] [Related]
60. [Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):624-628. PubMed ID: 32867452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
